Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral Oncogene homolog genotype in U.S. community-based oncology practices

Clinical Colorectal Cancer

Volumn 13, Issue 3, 2014, Pages 178-184

  Landsman Blumberg, Pamela B ^a   Carter, Gebra Cuyun ^b   Johnson, Barbara H ^a   Sedgley, Robert ^a   Nicol, Steven J ^b   Li, Li ^b   Shankaran, Veena ^c  

^a IBM WATSON HEALTH   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Electronic medical records; Guidelines; KRAS testing; NCCN; Real world treatment patterns

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINATE CALCIUM; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; CAMPTOTHECIN; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLINIC ACID; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; ONCOGENE K RAS; ONCOLOGY; PROFESSIONAL PRACTICE; PUBLIC HEALTH; SPLEEN METASTASIS; TREATMENT DURATION; UNITED STATES; WILD TYPE; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; COMMUNITY CARE; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PRACTICE GUIDELINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMMUNITY HEALTH SERVICES; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; YOUNG ADULT;

EID: 84908168107     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.05.001     Document Type: Article

References (27)

1. A. Benson, T. Bekaii-Saab, and E. Chan Metastatic colon cancer, Version 3.2013: featured updates to the NCCN guidelines J Natl Compr Canc Netw 11 2013 141 152
2. G.P. Hess, P.F. Wang, D. Quach, B. Barber, and Z. Zhao Systematic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice J Oncol Pract 6 2010 301 307
3. A. Cercek, and L. Saltz Evolving treatment of advanced colorectal cancer Curr Oncol Rep 12 2010 153 159
4. S. Kopetz, G.J. Change, and M.J. Overman Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 2009 3677 3683
5. R.M. Goldberg, M.L. Rothenberg, and E. VanCutsem The continuum of care: a paradigm for the management of metastatic colorectal cancer Oncologist 12 2007 38 50
6. E. Van Cutsem, I. Lang, and G. D'heans KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience J Clin Oncol (Meeting Abstracts) 26 15 suppl 2 2008
7. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience J Clin Oncol (Meeting Abstracts) 26 15 suppl 4000 2008
8. C. Allegra, J.M. Jessup, and M.R. Somerfield American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2009 2091 2096
9. A. Lièvre, P. Artru, and M. Guiu The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011 Eur J Cancer 49 2013 2126 2133
10. A. Vkjayaraghavan, M.B. Efrusy, B. Göke, T. Kirchner, C.C. Santas, and R.M. Goldberg Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany Int J Cancer 131 2012 438 445
11. J. Webster, T.L. Kauffman, and H.S. Feigelson KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings Cancer Epidmiol Biomarkers Prev 22 2012 91 101
12. Carter GC, Landsman-Blumberg P, Johnson BH, Sedgley R, Shankaran V. KRAS testing of mCRC patients in a community-based oncology setting. Gastrointestinal Cancers Symposium 2009; abstract 364.
13. Wasan H, Maddern J, Wilson R. Comparison of the rate of KRAS mutation testing in the UK and Europe in colorectal cancer. 8th NCRI Cancer Conference, Liverpool, UK 2012; abstract LB72.
14. F. Ciardiello, S. Teipar, and N. Normanno Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia Target Oncol 6 2011 133 145
15. S.F. Thompson, S.U. Iqbal, and S. Naoshy Current practices in 1st- (1L), 2nd- (2L), and 3rd-lind (3L) treatment for metastatic colorectal cancer (mCRC) J Clin Oncol 30 suppl 15 2012 e14028
16. Z. Zhao, E. Pelletier, and B. Barber Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe Curr Med Res Opin 28 2012 221 229
17. P.J. Miller, M.S. Walker, P. Landsman-Blumberg, and G.C. Carter Using text mining of electronic medical records to identify KRAS testing status in mCRC patients Value Health 16 2013 A21
18. X. Song, Z. Zhao, B. Barber, C. Gregory, P.F. Wang, and S.R. Long Treatment patterns and metastatasectomy among mCRC patients recieving chemotherapy and biologics Curr Med Res Opin 27 2011 123 130
19. R. Siegel, C. DeSantis, and K. Virgo Cancer treatment and survivorship statistics CA Cancer J Clin 62 2012 220 241
20. J. Bennouna, J. Sastre, and D. Arnold Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncol 14 2013 29 37
21. A. Grothey, M.M. Sugrue, and D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
22. G.M. Boland, G.J. Chang, and A.B. Haynes Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer Cancer 119 2013 1593 1601
23. R. Chagpar, Y. Xing, and Y.J. Chiang Adherence to stage-specific treatment guidelines for patients with colon cancer J Clin Oncol 30 2012 972 979
24. L.B. Saltz, H.J. Lenz, and H.L. Kindler Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561
25. J.R. Hecht, E. Mitchell, and T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
26. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
27. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, E.T. McFadden, and P.P. Carbone Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655